PainReform Ltd
NASDAQ:PRFX
PainReform Ltd
Research & Development
PainReform Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PainReform Ltd
NASDAQ:PRFX
|
Research & Development
-$11.7m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-142%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Research & Development
-$1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
4%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Research & Development
-$24.4m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Research & Development
-$12.8m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Research & Development
-₪4.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-5%
|
|
PainReform Ltd
Glance View
PainReform Ltd. operates as a pharmaceutical company. The Company’s main activity is to develop reformulation of established pain therapeutics. PainReform Ltd provides technology, which is dedicated to prolong and enhance efficacy, minimize adverse effects and increase patients convenience as well as faster return of motor function.
See Also
What is PainReform Ltd's Research & Development?
Research & Development
-11.7m
USD
Based on the financial report for Dec 31, 2024, PainReform Ltd's Research & Development amounts to -11.7m USD.
What is PainReform Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-142%
Over the last year, the Research & Development growth was -94%. The average annual Research & Development growth rates for PainReform Ltd have been -60% over the past three years , -142% over the past five years .
